Two years ago, the conversation about GLP-1 medications was dominated by access, cost, and side effects. The dietary part of the equation was an afterthought — “eat less, you’ll be hungry less” was about as deep as it got.
That era is over. With several million Americans now on semaglutide, tirzepatide, or one of the newer agents, the clinical playbook for how to eat on these medications has crystallized into something specific. We spent the last six weeks talking to dietitians, endocrinologists, and patients about what’s actually working in 2026.
Here is what’s emerged.
The new consensus on protein
The single most-emphasized point across every clinician we spoke to: protein intake matters more on a GLP-1 than off of it.
The mechanism is straightforward. GLP-1s produce a substantial calorie deficit, often 500–1,000 kcal per day below the patient’s previous intake. That deficit drives weight loss — but without dietary protection, a meaningful portion of that weight loss is lean mass rather than fat mass. The published trial data and the early real-world follow-up converge on the same warning: somewhere between 25% and 40% of weight lost on GLP-1 monotherapy, without nutrition intervention, is lean tissue.
The countermeasure is protein. Most clinicians we spoke to recommend a floor of 1.0–1.2 g/kg of body weight per day for patients on GLP-1s. For older patients (over 60), patients with sarcopenia risk, or patients simultaneously trying to maintain or build muscle through resistance training, the recommendation moves up to 1.4–1.6 g/kg.
For a 200-pound (90 kg) patient on a GLP-1, that’s 90–144 grams of protein per day — often a significant increase from where they were before starting the medication, and challenging to hit when appetite is reduced by 30–50%.
The practical implication: protein-first meals. Several dietitians described the shift in their patient counseling: “I used to talk about overall calorie balance and macro distribution. Now I tell GLP-1 patients to build every meal around the protein source first, and let everything else follow.”
The food-preference shift
A consistent observation across patients and clinicians: GLP-1s do not just reduce appetite generally. They reshape food preferences in fairly consistent ways.
The reductions are most pronounced for:
- Sweet foods, especially desserts and sugary drinks
- Very high-fat foods, especially fried foods
- Alcohol (this one has its own large literature now)
- Highly processed snack foods
The relative increases — meaning these foods feel more appealing relative to the others — tend to be:
- Lean proteins
- Vegetables and lower-density carbohydrates
- Acidic, savory, and umami flavors
Clinicians are using this as an opportunity. “The medication is doing the hard part for me,” one dietitian told us. “My job is to make sure the eating pattern they settle into is the one they’ll want to keep when they eventually titrate down or come off the medication.”
That framing is now standard. The dietary intervention isn’t a temporary scaffold around the drug; it’s a long-term pattern being built while the appetite reduction makes it easier to do.
Resistance training is non-optional
Every clinician we spoke to mentioned resistance training, unprompted. This is new. Two years ago the conversation was about diet. Now it’s about diet plus resistance training as a coupled intervention.
The evidence base for “protein plus resistance training preserves lean mass under deficit” predates the GLP-1 era — it comes from the bodybuilding science literature (Helms, Aragon, Phillips). What’s changed is that the literature has been pulled into mainstream weight-management practice.
The recommendation pattern: 2–3 resistance training sessions per week, full-body or split, with progressive overload. Weight-bearing only beats nothing; structured resistance training beats weight-bearing alone.
Clinicians acknowledged that adherence is the challenge. Many GLP-1 patients have not previously been exercisers. The framing several clinicians said worked: “you’re not training to lose weight — the medication is doing that. You’re training to keep the muscle that the medication doesn’t care about.”
Hydration, fiber, and the GI side effects
The most-cited dietary fixes for the most-common GLP-1 side effects:
Nausea: smaller meals more frequently, low-fat options, ginger, and avoiding very high-volume meals. Several clinicians recommended patients eat slowly and stop at the first signal of fullness, which on GLP-1s comes much earlier than it used to.
Constipation: substantially increased fiber (25–35 g per day), explicit hydration targets (often 80+ oz of water per day), and physical activity. Some clinicians recommend a magnesium citrate supplement; most prefer dietary intervention first.
Reflux: smaller meals, avoiding lying down within 2–3 hours of eating, and sometimes temporary food eliminations (caffeine, alcohol, very acidic foods).
The consistent theme: side effects are usually manageable with dietary adjustments before pharmacological ones.
Tracking and accountability
A meaningful number of GLP-1 patients are now using calorie and macro tracking apps as part of their treatment, often at their dietitian’s suggestion. The use case is different from traditional dieting: the goal isn’t to drive intake down (the medication is doing that), it’s to make sure intake is composed correctly — enough protein, enough fiber, enough variety, enough total intake to avoid undereating.
Several dietitians we spoke to mentioned PlateLens specifically as one of the apps they recommend to GLP-1 patients, citing the protein-forward dashboard and the photo logging that lets patients log a small meal in a few seconds. Others mentioned MacroFactor (for the adaptive math, useful when intake is changing rapidly), and Cronometer (for the micronutrient depth, which matters when total intake is low). The pattern: clinicians are recommending tools that match the specific GLP-1 challenge of getting enough of the right things while eating less overall.
What this looks like in practice
Synthesizing across the conversations, the clinical playbook for nutrition on GLP-1s in 2026 looks roughly like this:
- Protein floor: 1.0–1.2 g/kg, higher for older patients or those building muscle
- Build meals protein-first: choose the protein, then the vegetable, then the carb
- Resistance training: 2–3 sessions per week, progressive
- Fiber: 25–35 g per day, mostly from food
- Hydration: 80+ oz of water per day
- Tracking: optional but useful for ensuring composition, not for restricting intake
- Eat slowly: stop at fullness, which arrives early
- Long-term thinking: build the eating pattern you want to keep, not the one you can tolerate while medicated
This is a substantially more nuanced playbook than the one in circulation a year ago. The clinical community has caught up to the medication. The patients who are doing best are the ones whose providers have caught up too.
What was a pharmacological intervention in 2023 is, in 2026, a pharmacological-plus-nutritional-plus-resistance-training intervention. The medication makes the other parts easier. The other parts make the medication’s effects last.
